Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Short Interest Down 24.7% in April

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 48,120 shares, a decline of 24.7% from the March 31st total of 63,946 shares. Based on an average trading volume of 25,429 shares, the short-interest ratio is presently 1.9 days. Currently, 0.6% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BNR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen raised shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech has an average rating of “Sell”.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock traded up $1.09 during mid-day trading on Thursday, hitting $17.33. 60,443 shares of the company’s stock traded hands, compared to its average volume of 28,887. The firm has a 50 day simple moving average of $20.36 and a two-hundred day simple moving average of $20.76. Burning Rock Biotech has a fifty-two week low of $2.18 and a fifty-two week high of $41.72. The stock has a market cap of $186.43 million, a price-to-earnings ratio of -21.93 and a beta of 1.59.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share for the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.The firm had revenue of $18.05 million for the quarter.

Insider Activity

In related news, Director Yusheng Han bought 314,870 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was bought at an average cost of $17.36 per share, for a total transaction of $5,466,143.20. Following the transaction, the director owned 17,672,676 shares of the company’s stock, valued at $306,797,655.36. This represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 30.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BNR. China Universal Asset Management Co. Ltd. acquired a new position in shares of Burning Rock Biotech during the third quarter worth $26,000. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech during the fourth quarter worth $220,000. Prospera Financial Services Inc acquired a new position in shares of Burning Rock Biotech in the third quarter valued at approximately $214,000. Finally, Crcm LP increased its stake in shares of Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after buying an additional 26,809 shares during the period. 30.03% of the stock is currently owned by institutional investors and hedge funds.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.